ASSESSING THE SAFETY AND EFFICACY OF A 2MG DOSE OF TH9507, A GROWTH HORMONE RELE

评估 2 毫克剂量 TH9507（一种生长激素相关药物）的安全性和有效性

• 批准号: 7731337
• 负责人: STEVEN K. GRINSPOON
• 金额: $ 1.56万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731337
• 关键词: Body Composition; Central obesity; Computer Retrieval of Information on Scientific Projects Database; Dose; Exhibits; Funding; Goals; Grant; HIV; HIV-Associated Lipodystrophy Syndrome; High Density Lipoprotein Cholesterol; Hyperinsulinism; Institution; Insulin-Like Growth Factor I; Link; Lipids; Lipodystrophy; Metabolic; Obesity; Patients; Pharmaceutical Preparations; Population; Quality of life; Research; Research Personnel; Resources; Safety; Somatotropin; Somatotropin-Releasing Hormone; Source; TH9507; Triglycerides; United States National Institutes of Health; Visceral; abdominal fat; antiretroviral therapy; impaired glucose tolerance

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary goal of the stduy is to determine the safety and efficacy of the medication TH9507, a growth hormone releasing factor, in reducing excess visceral adiposity associated with HIV lipodystrophy. Secondary objectives include improvements in total cholesterol/HDL ratio, triglyceride levels, changes in IGF-1 and improvement in quality of life and characterization of the safety profile of TH9507 treatment in HIV subjects with excess abdominal fat accumulation. HIV infected patients treated with antiretroviral therapy commonly exhibit body composition changes and metabolic abnormalities, termed the HIV lipodystrophy syndrome. Increased visceral adiposity has been associated with abnormal lipid profiles, hyperinsulinemia and impaired glucose tolerance in this population. Reduced growth hormone levels have been implicated as a potential link between abdominal obesity and metabolic disturbances.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 STDUY的主要目标是确定药物Th9507（一种生长激素释放因子）的安全性和功效，以减少与HIV脂肪营养不良相关的过量内脏肥胖。 次要目标包括改善总胆固醇/HDL比，甘油三酸酯水平，IGF-1的变化以及生活质量的改善以及TH9507治疗的安全性特征的艾滋病毒受试者的安全特征的表征，腹部脂肪过多。 用抗逆转录病毒治疗治疗的HIV感染患者通常表现出人体组成变化和代谢异常，称为HIV脂肪营养不良综合征。 内脏肥胖的增加与该人群中脂质异常，高胰岛素血症和葡萄糖耐受性受损有关。 降低的生长激素水平被认为是腹部肥胖与代谢障碍之间的潜在联系。